Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 11/20 | 0.40 |
| ▸ | CNR1 | P21554 | 8/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565950 | 0.75 | HDAC1 (0.48) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL565105 | 0.74 | KDM4E (0.42) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL176994 | 0.73 | S1PR1 (0.75) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL565785 | 0.71 | S1PR1 (0.66) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL566524 | 0.69 | S1PR1 (0.43) | S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7346173 | 0.68 | KDM4E (0.65) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL177127 | 0.68 | S1PR1 (0.75) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL5446754 | 0.65 | KDM4E (0.52) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL2041412 | 0.65 | CNR2 (0.65) | S1PR1KDM4ECNR2CNR1IDO1 | |
| SCHEMBL29051451 | 0.65 | KDM4E (0.74) | S1PR1KDM4ECNR2IDO1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885KDM4E 1701/4885CNR2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.